Amgen, Inc. executives have been outspoken about the impact Medicare drug price negotiation under the Inflation Reduction Act (IRA) will have on the biopharmaceutical industry, but the pricing and reimbursement landscape in the US has become more challenging not just because of government policy shifts but also from increasingly difficult commercial payer negotiations.
Amgen’s Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters
Launches Have Longer Ramp-Up In High-Pressure Markets
Scrip spoke with Amgen’s senior VP of US business operations about the impact of drug pricing and reimbursement pressures coming from government policy changes and commercial payers.
More from New Products
More from Scrip
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.